[go: up one dir, main page]

NO20063676L - Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer - Google Patents

Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer

Info

Publication number
NO20063676L
NO20063676L NO20063676A NO20063676A NO20063676L NO 20063676 L NO20063676 L NO 20063676L NO 20063676 A NO20063676 A NO 20063676A NO 20063676 A NO20063676 A NO 20063676A NO 20063676 L NO20063676 L NO 20063676L
Authority
NO
Norway
Prior art keywords
inhibitors
indole derivatives
kinase inhibitors
particular ikk2
kinase
Prior art date
Application number
NO20063676A
Other languages
English (en)
Inventor
Paul Bamborough
Lan Robert Baldwin
John Andrew Christopher
Jeffrey K Kerns
Timothy Longstaff
David Drysdale Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20063676L publication Critical patent/NO20063676L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)

Abstract

Indolkarboksamid forbindelser med Formel (I) er tilveiebrakt som inhibitorer av kinaseaktivitet, særlig IKK2-aktivitet, så vel som sammensetninger og medikamenter som inneholder dem, for anvendelse ved inflammasjons- og vevsrepareringsforstyrrelser.
NO20063676A 2004-01-15 2006-08-15 Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer NO20063676L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0400895.9A GB0400895D0 (en) 2004-01-15 2004-01-15 Chemical compounds
PCT/GB2005/000085 WO2005067923A1 (en) 2004-01-15 2005-01-13 Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors

Publications (1)

Publication Number Publication Date
NO20063676L true NO20063676L (no) 2006-10-13

Family

ID=31726240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063676A NO20063676L (no) 2004-01-15 2006-08-15 Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer

Country Status (23)

Country Link
US (1) US20080269200A1 (no)
EP (1) EP1703905B1 (no)
JP (2) JP4975447B2 (no)
KR (1) KR20070026357A (no)
CN (1) CN1933830A (no)
AT (1) ATE413877T1 (no)
AU (1) AU2005205090A1 (no)
BR (1) BRPI0506802A (no)
CA (1) CA2552953A1 (no)
DE (1) DE602005010970D1 (no)
DK (1) DK1703905T3 (no)
ES (1) ES2317184T3 (no)
GB (1) GB0400895D0 (no)
HR (1) HRP20090071T3 (no)
IL (1) IL176739A0 (no)
MA (1) MA28279A1 (no)
NO (1) NO20063676L (no)
PL (1) PL1703905T3 (no)
PT (1) PT1703905E (no)
RU (1) RU2006129492A (no)
SI (1) SI1703905T1 (no)
WO (1) WO2005067923A1 (no)
ZA (1) ZA200604855B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR050253A1 (es) * 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20080021077A (ko) * 2005-06-30 2008-03-06 스미스클라인 비참 코포레이션 화합물
EP1940296A2 (en) * 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemical compounds
JP2009516702A (ja) * 2005-11-18 2009-04-23 スミスクライン・ビーチャム・コーポレイション 化合物
JP2009519968A (ja) * 2005-12-16 2009-05-21 スミスクライン・ビーチャム・コーポレイション 化学物質
PL2119703T3 (pl) * 2007-01-15 2013-04-30 Santen Pharmaceutical Co Ltd Nowe pochodne indolu o aktywności hamującej kinazę-ßIκB
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2009100130A1 (en) * 2008-02-04 2009-08-13 Mercury Therapeutics, Inc. Ampk modulators
EP2253618A1 (en) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
KR20110031481A (ko) * 2008-07-14 2011-03-28 산텐 세이야꾸 가부시키가이샤 카르바모일기, 우레이드기 및 치환 옥시기를 갖는 신규 인돌 유도체
WO2010101299A1 (ja) * 2009-03-05 2010-09-10 住友化学株式会社 ハロゲン置換ベンゼンジメタノールの製造方法
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
WO2014036268A2 (en) * 2012-08-29 2014-03-06 Mount Sinai School Of Medicine Indole derivatives as sumo activators
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
EP3070085B1 (en) * 2013-02-04 2019-01-09 Janssen Pharmaceutica NV Flap modulators
WO2014210255A1 (en) * 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
JP6644792B2 (ja) * 2014-12-18 2020-02-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンザゼピンスルホンアミド化合物
US20170158702A1 (en) * 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Multivalent ras binding compounds
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
WO2018223819A1 (zh) * 2017-06-07 2018-12-13 中国中医科学院中药研究所 一种吲哚乙酸类衍生物及其制备方法和医药用途
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2024059220A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775761A (en) * 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
DE3342632A1 (de) * 1983-11-25 1985-06-05 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
US5256673A (en) * 1983-11-25 1993-10-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
JPH0262875A (ja) * 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
US5254473A (en) * 1990-03-16 1993-10-19 Jp Laboratories Solid state device for monitoring integral values of time and temperature of storage of perishables
US5330986A (en) * 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
DE19756036A1 (de) * 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
CA2380373A1 (en) * 1999-08-13 2001-02-22 Seth Lederman Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
US6245799B1 (en) * 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
AU2001255538B2 (en) * 2000-04-24 2006-03-30 Bristol-Myers Squibb Company Heterocycles that are inhibitors of IMPDH enzyme
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
RU2003106192A (ru) * 2000-09-06 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Способ лечения аллергий
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
NZ525474A (en) * 2000-10-26 2005-10-28 Tularik Inc Antiinflammation agents
KR100600240B1 (ko) * 2001-06-07 2006-07-13 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
AU2002341729A1 (en) * 2001-09-19 2003-04-01 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
MXPA04004064A (es) * 2001-10-30 2004-09-06 Pharmacia Corp Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
EP1495016A2 (en) * 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
AR039280A1 (es) * 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
WO2004050634A1 (en) * 2002-12-02 2004-06-17 F. Hoffmann-La Roche Ag Indazole derivatives as crf antagonists
EP1569924A4 (en) * 2002-12-06 2007-02-21 Smithkline Beecham Corp NF-KB FACTOR INHIBITORS
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE102004012069A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
AR050253A1 (es) * 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
KR20130136010A (ko) * 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
ES2372701T3 (es) * 2005-07-22 2012-01-25 Shionogi & Co., Ltd. Derivado de indol que tiene actividad antagonista del receptor de pgd2.
EP1940296A2 (en) * 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemical compounds
EP1940394A4 (en) * 2005-10-25 2009-07-08 Smithkline Beecham Corp CHEMICAL COMPOUNDS
JP2009516702A (ja) * 2005-11-18 2009-04-23 スミスクライン・ビーチャム・コーポレイション 化合物
JP2009519968A (ja) * 2005-12-16 2009-05-21 スミスクライン・ビーチャム・コーポレイション 化学物質
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
US20080146606A1 (en) * 2006-09-22 2008-06-19 Paul Bamborough Novel compounds
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
GB0400895D0 (en) 2004-02-18
EP1703905B1 (en) 2008-11-12
CN1933830A (zh) 2007-03-21
ES2317184T3 (es) 2009-04-16
US20080269200A1 (en) 2008-10-30
ZA200604855B (en) 2007-11-28
CA2552953A1 (en) 2005-07-28
BRPI0506802A (pt) 2007-05-29
RU2006129492A (ru) 2008-02-27
JP2007517848A (ja) 2007-07-05
MA28279A1 (fr) 2006-11-01
HK1098047A1 (en) 2007-07-13
SI1703905T1 (sl) 2009-04-30
AU2005205090A1 (en) 2005-07-28
PL1703905T3 (pl) 2009-04-30
JP2012025761A (ja) 2012-02-09
HRP20090071T3 (en) 2009-04-30
IL176739A0 (en) 2006-10-31
ATE413877T1 (de) 2008-11-15
DE602005010970D1 (de) 2008-12-24
KR20070026357A (ko) 2007-03-08
JP4975447B2 (ja) 2012-07-11
WO2005067923A1 (en) 2005-07-28
EP1703905A1 (en) 2006-09-27
PT1703905E (pt) 2009-02-04
DK1703905T3 (da) 2009-02-16

Similar Documents

Publication Publication Date Title
NO20063676L (no) Indolderivater og anvendelse derav som kinaseinhibitorer i spesielle IKK2 inhibitorer
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
NO20071593L (no) Pyrimidinderivater
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
MX2008001538A (es) Aril piridinas y metodos para su uso.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application